Dianthus Therapeutics (DNTH)
78.06
-4.45 (5.39%)
Upcoming Events
Latest Headlines
Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'
June 12, 2026 2:53 PM - StreetInsider
Form 8-K Dianthus Therapeutics, For: Jun 12
June 12, 2026 7:01 AM - SEC Filing
Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'
June 10, 2026 4:10 PM - StreetInsider
Dianthus Therapeutics (DNTH) PT Raised to $132 at Jefferies
June 10, 2026 3:52 PM - StreetInsider
TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'
June 10, 2026 1:37 PM - StreetInsider
Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'
June 10, 2026 1:01 PM - StreetInsider
Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'
June 10, 2026 10:40 AM - StreetInsider
Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'
June 10, 2026 10:38 AM - StreetInsider
Dianthus Therapeutics (DNTH) Reiterated at Buy by Stifel
June 10, 2026 7:21 AM - StreetInsider
Form 4 Dianthus Therapeutics, For: Jun 01 Filed by: Randhawa Simrat
June 2, 2026 7:00 PM - SEC Filing
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026 4:01 PM - Globe NewsWire
Form 144 Dianthus Therapeutics, Filed by: Randhawa Simrat
June 1, 2026 4:14 PM - SEC Filing
Dianthus Therapeutics to Participate in Two Investor Conferences
May 26, 2026 4:01 PM - Globe NewsWire
Form 4 Dianthus Therapeutics, For: May 21 Filed by: Read Simon
May 22, 2026 4:30 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: May 21 Filed by: Lawton Alison Frances
May 22, 2026 4:30 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: May 21 Filed by: Romano Steven J.
May 22, 2026 4:30 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: May 21 Filed by: McGeorge Anne
May 22, 2026 4:30 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: May 21 Filed by: Violin Jonathan
May 22, 2026 4:30 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: May 21 Filed by: KANGO SUJAY
May 22, 2026 4:30 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: May 21 Filed by: Soteropoulos Paula
May 22, 2026 4:30 PM - SEC Filing
Form 8-K Dianthus Therapeutics, For: May 21
May 22, 2026 4:10 PM - SEC Filing
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
May 19, 2026 3:00 PM - Globe NewsWire
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 4:46 PM - SEC Filing
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:34 PM - SEC Filing
Form SCHEDULE 13G Dianthus Therapeutics, Filed by: Sirenia Capital Management LP
May 15, 2026 8:14 AM - SEC Filing
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
May 15, 2026 7:25 AM - SEC Filing
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Octagon Capital Advisors LP
May 14, 2026 4:02 PM - SEC Filing
Intellia short interest rises most among biotech stocks in latest period - Baird
May 12, 2026 9:58 AM - StreetInsider
Form 4 Dianthus Therapeutics, For: May 08 Filed by: Soteropoulos Paula
May 11, 2026 5:00 PM - SEC Filing
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
May 5, 2026 10:57 PM - Globe NewsWire
Dianthus Therapeutics (DNTH) Misses Q1 EPS by 85c
May 5, 2026 5:27 PM - StreetInsider
Form 10-Q Dianthus Therapeutics, For: Mar 31
May 5, 2026 4:08 PM - SEC Filing
Form 8-K Dianthus Therapeutics, For: May 05
May 5, 2026 4:04 PM - SEC Filing
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 5, 2026 4:01 PM - Globe NewsWire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026 4:30 PM - Globe NewsWire
Form SCHEDULE 13G Dianthus Therapeutics, Filed by: BlackRock, Inc.
April 27, 2026 4:14 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: Apr 09 Filed by: Savitz Ryan
April 10, 2026 4:52 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan
April 9, 2026 4:23 PM - SEC Filing
Form ARS Dianthus Therapeutics, For: Dec 31
April 9, 2026 4:12 PM - SEC Filing
Form DEFA14A Dianthus Therapeutics,
April 9, 2026 4:11 PM - SEC Filing
Form DEF 14A Dianthus Therapeutics, For: May 21
April 9, 2026 4:09 PM - SEC Filing
Wolfe Research Starts Dianthus Therapeutics (DNTH) at Outperform
April 8, 2026 4:32 PM - StreetInsider
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026 4:01 PM - Globe NewsWire
Form 4 Dianthus Therapeutics, For: Mar 31 Filed by: Savitz Ryan
April 1, 2026 5:27 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: Mar 31 Filed by: Soteropoulos Paula
April 1, 2026 5:26 PM - SEC Filing
William Blair Shuffles Analyst Conviction List for April 2026
April 1, 2026 7:15 AM - StreetInsider
Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan
March 31, 2026 4:25 PM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Soteropoulos Paula
March 31, 2026 4:21 PM - SEC Filing
Form 4 Dianthus Therapeutics, For: Mar 24 Filed by: Soteropoulos Paula
March 26, 2026 6:00 PM - SEC Filing
William Blair on Dianthus Therapeutics (DNTH): FDA removing ANA criteria 'an incremental positive'
March 26, 2026 10:54 AM - StreetInsider
Form 8-K Dianthus Therapeutics, For: Mar 26
March 26, 2026 8:01 AM - SEC Filing
Form 144 Dianthus Therapeutics, Filed by: Soteropoulos Paula
March 24, 2026 4:30 PM - SEC Filing
Wells Fargo Reiterates Overweight Rating on Dianthus Therapeutics (DNTH)
March 19, 2026 5:23 AM - StreetInsider
Full Article List
